| __timestamp | Insmed Incorporated | Takeda Pharmaceutical Company Limited |
|---|---|---|
| Wednesday, January 1, 2014 | 33534999 | 520990000000 |
| Thursday, January 1, 2015 | 1982000 | 535405000000 |
| Friday, January 1, 2016 | 2438000 | 558755000000 |
| Sunday, January 1, 2017 | 2901000 | 495921000000 |
| Monday, January 1, 2018 | 2423000 | 659690000000 |
| Tuesday, January 1, 2019 | 24212000 | 1089764000000 |
| Wednesday, January 1, 2020 | 39872000 | 994308000000 |
| Friday, January 1, 2021 | 44152000 | 1106846000000 |
| Saturday, January 1, 2022 | 55126000 | 1244072000000 |
| Sunday, January 1, 2023 | 65573000 | 1431505000000 |
| Monday, January 1, 2024 | 1431505000000 |
Infusing magic into the data realm
In the ever-evolving pharmaceutical industry, cost efficiency is a critical metric for success. This analysis delves into the cost of revenue trends for Takeda Pharmaceutical Company Limited and Insmed Incorporated from 2014 to 2023. Over this period, Takeda's cost of revenue has shown a remarkable increase of approximately 175%, peaking at 1.43 trillion in 2023. In contrast, Insmed's cost of revenue, while significantly smaller, has grown by over 3,200%, reaching 65.57 million in 2023.
Takeda's consistent growth reflects its expansive global operations and robust product pipeline. Meanwhile, Insmed's rapid increase, albeit from a smaller base, highlights its aggressive expansion and investment in niche markets. Notably, data for Insmed in 2024 is missing, indicating potential reporting delays or strategic shifts. This comparison underscores the diverse strategies employed by pharmaceutical giants to navigate the complex landscape of cost management.
Comparing Cost of Revenue Efficiency: Novo Nordisk A/S vs Takeda Pharmaceutical Company Limited
Cost of Revenue Comparison: Amgen Inc. vs Insmed Incorporated
Comparing Cost of Revenue Efficiency: Takeda Pharmaceutical Company Limited vs Ionis Pharmaceuticals, Inc.
Cost of Revenue Comparison: Takeda Pharmaceutical Company Limited vs Xenon Pharmaceuticals Inc.
Cost Insights: Breaking Down Takeda Pharmaceutical Company Limited and HUTCHMED (China) Limited's Expenses
Comparing Cost of Revenue Efficiency: Takeda Pharmaceutical Company Limited vs Mesoblast Limited
Cost of Revenue Trends: Takeda Pharmaceutical Company Limited vs Travere Therapeutics, Inc.
Comparing Cost of Revenue Efficiency: Takeda Pharmaceutical Company Limited vs Xencor, Inc.
Cost of Revenue Trends: Takeda Pharmaceutical Company Limited vs BioCryst Pharmaceuticals, Inc.
Comparing Cost of Revenue Efficiency: United Therapeutics Corporation vs Insmed Incorporated
Comparing Cost of Revenue Efficiency: Insmed Incorporated vs Pharming Group N.V.
Cost of Revenue Comparison: Insmed Incorporated vs Veracyte, Inc.